Inherited genetic mutations can significantly increase the risk for prostate cancer (PC), may
be associated with aggressive disease and poorer outcomes, and can have hereditary …

Dramatic progress has been made in the area of germline genetics of prostate cancer (PCa)
in the past decade. Both common and rare genetic variants with effects on risk ranging from …

Abstract Background Prostate cancer (PCa) is a significant health burden for African men,
with mortality rates more than double global averages. The prostate specific Anoctamin 7 …

Significant progress has been made in genetic and genomic testing for prostate cancer
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …

In 2010, Archbishop Emeritus Desmond Tutu became the first African to contribute his
complete genome to science. 1 His vision, African inclusion in the benefits of genomic …

Simple Summary Identifying which men at the time of prostate cancer diagnosis have, or will
progress to, an aggressive fatal disease will allow clinicians to assist men in making better …

Background Prostate cancer (PCA) germline testing (GT) is now standard-of-care for men
with advanced PCA. Thousands of men may consider GT due to clinical and family history …

Background Prostate cancer is among the most heritable cancers, and clinical testing for
germline genetic variants based on ethnicity, disease features, and family history has …

5003 Background: Prostate cancer (PCa) incidence, mortality, and outcomes vary widely
across race/ethnicity. The underlying drivers of these differences are multifactorial, including …

Background The goal of precision medicine in prostate cancer (PCa) is to individualize the
treatment according to the patient's germline mutation status. PCa has a very high rate of …